IP Library Granted Patent US 8,404,471
Granted Patent B2
US 8,404,471 · App. 12/492,925 · Granted Mar 26, 2013

Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities

Inventors: Leslie Ann Greene (San Diego, CA); Ryan Andrew Adams (San Diego, CA); Fei Hong (San Diego, CA); Ji Zhao (San Diego, CA); Eva Rebecka Stephanie Armour (San Diego, CA); Kristi Helen Piehl (San Diego, CA)
Assignee: aTyr Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,471
App. No.
12/492,925
Granted
Mar 26, 2013
Kind
B2
Abstract

Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Claims (23)

1. An isolated glycyl-tRNA synthetase (GRS) polypeptide of up to about 500 amino acids in length that comprises amino acid residues 367-438 of SEQ ID NO:1, or a GRS variant of up to about 500 amino acids in length that comprises a sequence at least 95% identical to residues 367-438 of SEQ ID NO:1.

2. The isolated GRS polypeptide of claim 1 , where the GRS polypeptide comprises amino acid residues 367-438 of SEQ ID NO:1.

3. The isolated GRS polypeptide of claim 1 , where the GRS polypeptide comprises amino acid residues 214-438, 214-685, 239-685, 265-685, 311-685, or 333-685 of SEQ ID NO:1, or where the GRS variant comprises a sequence at least 95% identical to residues 214-438, 214-685, 239-685, 265-685, 311-685, or 333-685 of SEQ ID NO:1.

4. The isolated GRS polypeptide of claim 3 , where the GRS polypeptide comprises amino acid residues 214-438, 214-685, 239-685, 265-685, 311-685, or 333-685 of SEQ ID NO:1.

5. The isolated GRS polypeptide of claim 1 , where the GRS polypeptide or GRS variant is up to about 400 amino acids in length.

6. The isolated GRS polypeptide of claim 5 , where the GRS polypeptide comprises amino acid residues 367-438 of SEQ ID NO:1.

7. The isolated GRS polypeptide of claim 5 , where the GRS polypeptide comprises amino acid residues 214-438, 311-685, or 333-685 of SEQ ID NO:1, or where the GRS variant comprises a sequence at least 95% identical to residues 214-438, 311-685, or 333-685 of SEQ ID NO:1.

8. The isolated GRS polypeptide of claim 7 , where the GRS polypeptide comprises amino acid residues 214-438, 311-685, or 333-685 of SEQ ID NO:1.

9. The isolated GRS polypeptide of claim 1 , where the GRS polypeptide or GRS variant is up to about 300 amino acids in length.

10. The isolated GRS polypeptide of claim 9 , where the GRS polypeptide comprises amino acid residues 367-438 of SEQ ID NO:1.

11. The isolated GRS polypeptide of claim 9 , where the GRS polypeptide comprises amino acid residues 214-438 of SEQ ID NO:1, or where the GRS variant comprises a sequence at least 95% identical to residues 214-438 of SEQ ID NO:1.

12. The isolated GRS polypeptide of claim 11 , where the GRS polypeptide comprises amino acid residues 214-438 of SEQ ID NO:1.

13. The isolated GRS polypeptide of claim 11 , where the GRS polypeptide consists essentially of amino acid residues 214-438 of SEQ ID NO:1.

14. The isolated GRS polypeptide of claim 1 , where the GRS polypeptide or GRS variant is up to about 200 amino acids in length.

15. The isolated GRS polypeptide of claim 14 , where the GRS polypeptide comprises residues 367-438 of SEQ ID NO:1.

16. The isolated GRS polypeptide of claim 1 , where the GRS polypeptide or GRS variant is up to about 100 amino acids in length.

17. The isolated GRS polypeptide of claim 16 , where the GRS polypeptide comprises residues 367-438 of SEQ ID NO:1.

18. The isolated GRS polypeptide of claim 16 , where the GRS polypeptide consists essentially of residues 367-438 of SEQ ID NO:1.

19. The isolated GRS polypeptide claim 1 , where the GRS polypeptide or GRS variant is pegylated.

20. The isolated GRS polypeptide of claim 1 , where the GRS polypeptide or GRS variant is fused to a heterologous fusion partner.

21. The isolated GRS polypeptide of claim 20 , where the heterologous fusion partner comprises an Fc region.

22. A dimeric or multimeric complex comprising at least one isolated GRS polypeptide or GRS variant of claim 1 .

23. A composition comprising a physiologically acceptable carrier and at least one component selected from the group consisting of: (i) an isolated glycyl-tRNA synthetase (GRS) polypeptide or GRS variant of claim 1 ; (ii) a fusion protein comprising a GRS polypeptide or GRS variant of (i) and a heterologous fusion partner; and (iii) a dimeric or multimeric complex comprising at least one isolated GRS polypeptide or GRS variant of (i).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2009
From: GREENE, LESLIE ANN; ADAMS, RYAN ANDREW; HONG, FEI; ZHAO, JI; ARMOUR, EVA REBECKA STEPHANIE; PIEHL, KRISTI HELEN
To: ATYR PHARMA, INC.
Reel/Frame 023370/0577 →
Continuity (3)
Provisional Application 61095548 · Sep 9, 2008
Provisional Application 61076098 · Jun 26, 2008
Related Publication 20100028352A1 · Feb 4, 2010